ABSTRACT
Objective The aim of the study is to evaluate clinical efficacy and safety of azatreonam or ceftazidime on treatment of lower respiratory tract infection .Methods Four English databases (MEDLINE、EMBASE、Pubmed、Cochrane li‐brary) and three Chinese databases (CNKI、VIP、WANFANG) were searched .Meta‐analysis was performed using Review Manager 5 .2 .Results The Meta‐analysis revealed azatreonam was superior to ceftazidime in total efficiency (RR=1 .15 ,95%CI is 1 .09‐1 .21) .No significant differences are seen between azatreonam and ceftazidime (RR=1 .03 ,95% CI is 0 .98‐1 .09) on the bacterial eradication rates or the incidence of adverse reactions (RR=0 .66 ,95% CI is 0 .39‐1 .12) .Conclusion Azatreonam is more effective than ceftazidime on the treatment of lower respiratory tract infection in the clinical practice .
ABSTRACT
Objective To study the effect of euthyrox on blood lipids in patients with hypothyroidism throngh the meta analysis.Methods Patients with clinical hypothyroidism theated by euthyrox on blood lipid effect of randomized controlled trials were retried by Pubmed(2000/2014-07),EMbase (2000/2014-07),the Cochrane library(2014,7),the Chinese biomedical literature database(2000/2014-07),retrieved the time limit from January 2000 to July 2014.The paper were objective evaluated of the quality,Meta analysis with Rev Man 5.3 software system applicated by Cochrane collaboration.Results Euthyrox could significantly reduce cholesterol levels of hypothyroidism patients ,it was statistically significant difference(OR=0.63,95%CI:0.71 ~0.55,P<0.001);Euthyrox could significantly reduce triglyceride levels of hypothyroidism patients,difference was statistically significant(OR =0.29,95%CI:0.34 ~0.25,P <0.001 );Euthyrox could significantly reduce low-density lipoprotein cholesterol levels of hypothyroidism patients,it was statistically significant difference(OR=0.22,95%CI:0.30 ~0.14,P<0.001);euthyrox could obviously increase high-density lipoprotein cholesterol levels, it was statistically significant difference (OR =0.21, 95% CI:0.17 ~0.26, P <0.001 ). Conclusion Euthyrox could significantly reduce total cholesterol,triglyceride,low-density lipoprotein cholesterol(hdl-c)of hypothyroidism patients,and promote the synthesis of high-density lipoprotein cholesterol(hdl-c),could effectively promote the lipid metabolism,reduce blood fat level,prevent the happening of the disease of heart head blood-vessel hypothyroidism patients,have the guide meaning to clinical treatment.
ABSTRACT
Objective To approach the efficacy and safety of arotinolol in treating essential hypertension.Methods The studies about arotinolol in treating essential hypertension were accessed by searching the Cochrane Central Register of Controlled Trials(Issue 3,2008),MEDLINE(1991 to March 2009),EMbase(1991 to March 2009),CBMdisc(1991 to March 2009),and CNKI(1994 to March 2009).The relevant journals and conference proceedings also hand searched.Randomized controlled trials(RCTs) in which arotinolol was used to treat patients with essential hypertension were collected.Then the retrieved studies according to predefined inclusion and exclusion criteria were screened,the quality of included studies was evaluated,and Meta analysis was performed by using RevMan 4.2 software.Results A total of 176 articles were found and 6 of which were finally included.In homogeneity test:?2=4.41,df=7,P=0.73(efficacy);?2=2.96,df=4,P=0.56(safety).In combined test,Z=0.64(P=0.52),OR=1.17,OR95%CI(0.72-1.85)(efficacy);Z=1.75(P=0.08),OR=0.60,OR95%CI(0.34-1.06)(safety).Conclusion There is no significant difference in efficacy and safety between arotinolol and control group in treating essential hypertension.